

UNITED STATES PATENT AND TRADEMARK OFFICE

ED STATES DEBARTA

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/752,095	01/07/2004	Bill E. Cham	P07389US01/BAS	2329	
881	7590 11/09/2005		EXAMINER		
STITES & HARBISON PLLC			PESELE	PESELEV, ELLI	
1199 NORTH SUITE 900	I FAIRFAX STREET		ART UNIT	PAPER NUMBER	
	IA, VA 22314		1623		

DATE MAILED: 11/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	-		4		
		Applica	ation No.	Applicant(s)	
Office Action Summary		10/752	2,095	CHAM, BILL E.	
		Examir	ner	Art Unit	
	·	Elli Pes	elev	1623	
Period fo	 The MAILING DATE of this communication 	tion appears on	the cover sheet w	ith the correspondence add	dress
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL asions of time may be available under the provisions of 3' SIX (6) MONTHS from the mailing date of this communic period for reply is specified above, the maximum statute to reply within the set or extended period for reply will, reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF 7 CFR 1.136(a). In no lation. ary period will apply and by statute, cause the	THIS COMMUNIO event, however, may a red will expire SIX (6) MON application to become AB	CATION. reply be timely filed ITHS from the mailing date of this col BANDONED (35 U.S.C. § 133).	
Status					
2a)	Since this application is in condition for	☑ This action is allowance exce	s non-final. pt for formal matt	· •	merits is
	closed in accordance with the practice	under <i>Ex parte</i>	Quayle, 1935 C.D). 11, 453 O.G. 213.	
Dispositi	on of Claims				
5)□ 6)⊠ 7)□	Claim(s) <u>24-63</u> is/are pending in the apple 4a) Of the above claim(s) is/are vectoring is/are allowed. Claim(s) <u>24-63</u> is/are rejected. Claim(s) <u>is/are objected to.</u> Claim(s) is/are object to restriction	withdrawn from (
Applicati	on Papers				
9) 10)	The specification is objected to by the Entre drawing(s) filed on is/are: a) Applicant may not request that any objection Replacement drawing sheet(s) including the The oath or declaration is objected to by	accepted or n to the drawing(secorrection is req	s) be held in abeyar uired if the drawing	nce. See 37 CFR 1.85(a). (s) is objected to. See 37 CF	
Priority u	ınder 35 U.S.C. § 119				
12)	Acknowledgment is made of a claim for All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International see the attached detailed Office action for	cuments have be cuments have be he priority documents Bureau (PCT R	een received. een received in A ments have been tule 17.2(a)).	pplication No received in this National \$	Stage
2) Notice 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO- nation Disclosure Statement(s) (PTO-1449 or PTC r No(s)/Mail Date		Paper No(s	Summary (PTO-413) s)/Mail Date nformal Patent Application (PTO- 	-152)

Application/Control Number: 10/752,095

Art Unit: 1623

The disclosure is objected to because of the following informalities: the status of the parent application no. 09/958,333 has not been updated on page1 of the specification.

Appropriate correction is required.

Claims 29, 32, 50 and 53 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The terminology "an aqueous solvent" (claims 29 and 50) and "wherein a time period of at least about 7 days has elapsed between the extraction and removal steps" (claims 32 and 53) is not disclosed or suggested by the specification as originally filed.

Claims 1-63 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "derivative" (claims 24 and 43) renders the claims indefinite since it is not clear what is encompassed by said term i.e. the scope of the claimed invention cannot be determined. Note that the specification fails to provide a definition for said term. The use of the term "comprising" instead of "selected from" is improper in the Markush terminology ""X" is a radical selected from the group comprising" (claims 24 and 43).

Application/Control Number: 10/752,095

Art Unit: 1623

Regarding claims 25 and 44, the phrase "eg" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

Applicant's arguments filed June 25, 2004 have been fully considered but they are not persuasive.

Applicant contends that page 9 of the specification provides a definition for the term "derivative". However, page 9 of the specification provides description of the term "carbohydrate".

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24-63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cham et al (Cancer Letters, 5 (1990) 221-225).

The claims are directed to a method of preparing a glycoalkaloid preparation which includes the step of removing essentially all free sugars derived from the glycoalkaloid, compositions produced by such methods and and method of treating cancer.

Claims 49-52 also include the step of removing any aglycone from the glycoalkaloid preparation.

Cham et al disclose a glycoalkaloid composition useful for treating cancer. Cham et al also disclose the free rhamnose inhibits the efficacy of a glycoalkaloid composition

Application/Control Number: 10/752,095

Art Unit: 1623

and that an aglycone is not effective against cancer (see, for example, page 221, last paragraph). Therefore, a person having ordinary skill in the art at the time the instant invention was made would have been motivated to remove free sugars and aglycones from the a glycoalkaloid composition in order to improve its efficacy.

Applicant's arguments filed June 25, 2005 have been fully considered but they are not persuasive.

Applicant contends that Cham et al disclose addition of rhamnose to the glycoalkaloid preparation and does not disclose the inhibitory effect of the free sugars resulting from the degradation of the glycoalkaloids. This argument has not been found persuasive. Since rhamnose was known to have inhibitory effect on a glycoalkaloid preparation and aglycone was known to be ineffective in the treatment of cancer, a person having ordinary skill at the time the instant invention was made would have been motivated to remove sugars and aglycons from the glycoalkaloid preparation whether said sugars and aglycones are the result of degradation or addition.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 8.00-4.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/752,095 Page 5

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elli Peselev

ELLI PESELEV PRIMARY EXAMINER GROUP 1200